Global Home Global Home  
 
 

News

Date Title and Summary Additional Formats
Toggle Summary Sonoma Pharmaceuticals Receives Two New United Arab Emirates Regulatory Approvals: Pediacyn® For Atopic Dermatitis And Epicyn® For Scar Management
PETALUMA, Calif., April 12, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced it
View HTML
Toggle Summary Blog Coverage Sonoma Pharmaceuticals Announced FDA Clearance For Loyon Skin Descaler
Upcoming AWS Coverage on Amphastar Pharmaceuticals Post-Earnings Results
View HTML
Toggle Summary Sonoma Pharmaceuticals Receives U.S. FDA Clearance of Loyon® Skin Descaler for Relief of Scaling Associated with Various Dermatoses
PETALUMA, Calif., March 29, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced it
View HTML
Toggle Summary Sonoma Pharmaceuticals Receives Final $1.5 Million Payment from Sale of Latin America Business to Invekra S.A.P.I. de C.V.
PETALUMA, Calif., March 23, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Results from Sebuderm™ Gel Study in Treatment of Seborrheic Dermatitis
Evaluation of SebuDerm (hypochlorous acid) Gel on Mild to Moderate Facial and Scalp Seborrheic Dermatitis Investigator Global Assessment (IGA) Scores Showed a 33% Improvement at Day 14 and a 52% Improvement at Day 28 Clinical Poster being Presented at the 13th Annual Maui Dermatology Conference on
View HTML
Toggle Summary Petsmart® Launches The Microcynah® Family of Pet Healthcare Products for Dogs, Cats, Birds, Reptiles and Small Animals
PHOENIX and PETALUMA, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced that PetSmart, Inc., the leading pet specialty retailer in North America, has launched the company’s MicrocynAH® family of animal healthcare products this
View HTML
Toggle Summary Sonoma Pharmaceuticals Reports Financial Results for Fiscal Third Quarter 2017
U.S. Product Revenue up 65%, Driven by Growth in U.S. Dermatology Sales Cash Position of $20.5 Million; More Than Fully Funded to Achieve EBITDA Breakeven  Income From Discontinued Operations of $15.5 Million and Net Income of $16.2 Million Due to the Sale of Latin America Assets   Conference Call
View HTML
Toggle Summary Sonoma Pharmaceuticals Appoints Marc Umscheid as Chief Strategy and Marketing Officer
PETALUMA, Calif., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced the appointment of Marc Umscheid as chief strategy and marketing officer.  Previously, Umscheid worked at the Clorox Company where he most recently served as senior
View HTML
Toggle Summary With $19.5 Million In Coffers From Asset Sale, Sonoma Pharmaceuticals Sets Sights On Breakeven -- Secfilings.Com
REDONDO BEACH, CA--(Marketwired - Jan 26, 2017) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article examining Sonoma Pharmaceuticals' (NASDAQ: SNOA) recent sale of Latin American and
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Fiscal Third Quarter 2017 Financial Results and Conference Call
PETALUMA, Calif., Jan. 26, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced that the financial results for its fiscal third quarter 2017, ended December 31, 2016, will be released after the U.S. markets close on February 9, 2017.
View HTML